Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Michael Dickinson, Gloria Iacoboni et al.|Journal of Clinical Oncology|2021

Cited by 428